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Abstract	  
To	  determine	  whether	  systemic	  immunization	  with	  plasmid	  DNA	  and	  virus	  vector	  against	  visna/maedi	  virus	  
(VMV)	   would	   induce	   protective	   immune	   responses,	   sheep	   were	   immunized	   with	   VMV	   gag	   and/or	   env	  
sequences	   using	   particle-­‐mediated	   epidermal	   bombardment	   and	   injection	   of	   recombinant	   modified	  
vaccinia	  Ankara.	  The	  results	  showed	  that	  immunization	  induced	  both	  humoral	  and	  cell-­‐mediated	  responses	  
prior	   to	   and	   after	   virus	   challenge.	   The	   vaccination	   protocol	   did	   not	   prevent	   infection,	   but	   immunization	  
with	  the	  gag	  gene	  or	  a	  combination	  of	  gag	  and	  env	  genes	  resulted	  in	  significantly	  reduced	  provirus	  loads	  in	  
blood	   and	   mediastinal	   lymph	   node,	   respectively.	   Provirus	   loads	   in	   lung	   and	   draining	   lymph	   node	   were	  
unaffected,	  but	  p25	  expression	  was	  undetectable	  in	  lungs	  of	  animals	  immunized	  with	  a	  combination	  of	  gag	  
and	  env	  genes.	  Analysis	  of	   target	   tissues	   for	   lesions	  at	  post-­‐mortem	  showed	   that	   immunization	  with	   the	  
env	  gene	  caused	  a	  significant	  increase	  in	  lesion	  score,	  while	  the	  gag	  gene	  or	  a	  combination	  of	  gag	  and	  env	  
genes	   had	   no	   effect.	   Inclusion	   of	   the	   ovine	   interferon-­‐γ	   gene	   in	   the	   initial	   priming	  mixture	   had	  minimal	  
effect	  on	  immune	  responses,	  provirus	  load,	  or	  lesion	  development,	  although	  it	  resulted	  in	  a	  decreased	  p25	  
expression	  in	  the	  lung.	  The	  results	  thus	  show	  that	  systemic	  immunization	  with	  gag	  or	  a	  combination	  of	  gag	  
and	  env	  genes	  reduces	  provirus	  load	  in	  blood	  and	  lymphoid	  tissue,	  respectively	  whereas	  env	  immunization	  
has	  no	  effect	  on	  provirus	  load	  but	  increased	  lesion	  development.	  




Visna/maedi	   virus	   (VMV)	   and	   caprine	   arthritis	   encephalitis	   virus	   (CAEV)	   are	   members	   of	   the	   Lentivirus	  
genus	   and	   are	   collectively	   known	   as	   small	   ruminant	   lentiviruses	   (SRLV).	   These	   viruses	   cause	   slow	  
progressive	   infection	   of	   sheep	   and	   goats	   which	   results	   in	   the	   development	   of	   a	   multisystem	   disease	  
variably	   involving	   the	   lungs,	   brain,	   joints	   and	   mammary	   glands	   [1].	   VMV	   and	   CAEV	   target	   cells	   of	   the	  
monocyte	   macrophage	   lineage	   and	   do	   not	   infect	   T	   cells,	   in	   contrast	   to	   the	   related	   immunodeficiency	  
viruses	  of	  man	  (HIV),	  monkeys	  (SIV),	  and	  cats	  (FIV)	  [2],	  [3]	  and	  [4].	  Transmission	  of	  VMV	  and	  CAEV	  occurs	  
from	  infected	  mothers	  to	  offspring	  by	  ingestion	  of	  virus-­‐containing	  colostrum	  and	  milk	  and	  between	  adults	  
through	   contact	   with	   infected	   material	   such	   as	   respiratory	   secretions.	   Both	   humoral	   and	   cell-­‐mediated	  
immune	  responses	  are	  generated	  in	  the	  infected	  animals	  during	  the	  asymptomatic	  period,	  though	  these	  fail	  
to	  clear	  the	  virus	  and	  animals	  remain	  infected	  for	  life	  [1].	  
Several	   reports	  have	  addressed	  the	   issue	  of	  whether	  vaccination,	  especially	  with	  viral	  structural	  proteins,	  
could	   control	   SRLV.	   Inactivated	   virus	   was	   utilized	   in	   early	   studies.	   However,	   these	   resulted	   in	   the	  
appearance	  of	  exacerbated	  disease	  with	  more	  rapid	  onset	  [5],	  [6]	  and	  [7].	  Similarly,	  immunization	  of	  sheep	  
with	   an	   immunodominant	   T-­‐helper	   peptide	   derived	   from	   the	   CAEV	   GAG	   protein	   in	   adjuvant	   resulted	   in	  
increased	   virus	   load	   after	   intravenous	   challenge	   [8].	   The	   lesions	   in	   SRLV	   infections	   are	   thought	   to	   be	  
immune	  mediated,	   since	   immunosuppression	   reduces	   tissue	   inflammation	   [9],	   and	   depletion	   of	   CD4+	   T	  
cells	  causes	  a	  reduction	  in	  the	  number	  of	  virus-­‐infected	  macrophages	  in	  vivo	  [10].	  The	  results	  of	  the	  vaccine	  
studies	   were	   thus	   interpreted	   to	   mean	   that	   immunization	   simply	   resulted	   in	   immune	   responses	   that	  
stimulated	   virus	   replication	   and	   caused	   tissue	   damage.	   However,	   recently	   it	   has	   been	   shown	   that	  
immunization	  of	  goats	  with	  recombinant	  gp135	  glycoprotein	  of	  CAEV	  induces	  neutralizing	  antibodies	  [11],	  
suggesting	  that	  protective	  effects	  may	  be	  possible.	  Indeed,	  the	  use	  of	  plasmid	  DNA	  vaccination	  or	  live	  viral	  
vectors	   encoding	   CAEV	   env	   gene	   has	   demonstrated	   that	   reductions	   in	   virus	   load	   and	   disease	   can	   be	  
achieved	  [12].	  
Particle-­‐mediated	   epidermal	   delivery	   (PMED)	   has	   been	   used	   in	   many	   vaccine	   studies	   with	   increasing	  
success	  not	  only	  in	  rodent	  models	  but	  also	  in	  humans,	  non-­‐human	  primates	  and	  several	  veterinary	  species	  
[13].	  Comparisons	  of	  PMED	  with	  needle-­‐based	  approaches	  to	  DNA	  vaccine	  delivery	  show	  that	  PMED	  often	  
induces	   higher	   antibody	   and	  CD8+	   T	   cell	   responses	   [14]	   and	   [15].	   PMED	  has	   also	   been	   shown	   to	   induce	  
protective	  responses	  against	  SIV	  and	  herpesviruses	  at	  mucosal	  sites	  [16],	  [17]	  and	  [18].	  This	  feature	  would	  
be	   important	   for	   pathogens	   such	   as	   VMV	   and	   CAEV	   that	   use	   the	   mucosal	   route.	   In	   a	   recent	   study	   by	  
Gonzalez	  et	  al.	  [19],	  particle-­‐mediated	  bombardment	  of	  mucosal	  tissues	  was	  used	  to	  immunize	  sheep	  with	  
the	  VMV	  gene	   (env)	   encoding	   the	   two	  envelope	  proteins.	   The	   results	   showed	   reduced	   virus	   load	  over	   a	  
period	   of	   18	   months	   before	   the	   challenge	   virus	   re-­‐appeared.	   The	   results	   suggested	   that	   mucosal	  
immunization	  with	  the	  VMV	  env	  gene	  could	  dampen	  virus	  replication	  for	  an	  extended	  period.	  
In	   recent	   years,	   heterologous	   prime-­‐boost	   regimes	   have	   been	   assessed	   in	   vaccination	   development	  
whereby	  priming	  is	  achieved	  by	  plasmid	  DNA	  constructs	  and	  boosting	  by	  a	  recombinant	  (viral	  or	  bacterial),	  
recombinant	   proteins	   or	   synthetic	   peptides	   [20],	   [21]	   and	   [22].	   In	   addition,	   immune	  modulators	   such	   as	  
cytokines	  and	  chemokines	  have	  been	  included	  in	  the	  immunization	  protocol.	  In	  rodent	  models,	  molecular	  
adjuvants	  such	  as	  IFN-­‐γ,	  IL-­‐12,	  GM-­‐CSF	  often	  have	  profound	  effects	  on	  immune	  responses	  generated	  [23].	  
Recently,	  we	  investigated	  the	  effect	  of	  a	  prime-­‐boost	  protocol	  whereby	  sheep	  were	  immunized	  with	  VMV	  
gag	   gene	   (encoding	   the	   virus	   core	   proteins)	   and	   env	   gene	   via	   the	   respiratory	   tract.	   Plasmid	  
DNA/polyethylenimine	   complexes	  were	   used	   to	   prime	   and	   boost,	   then	   a	   recombinant	  modified	   vaccinia	  
Ankara	  vector	  encoding	  the	  same	  genes	  was	  given	  as	  a	  heterologous	  boost	  [24].	  The	  results	  showed	  that	  
env	   gene	   immunization	   induced	   reduced	   provirus	   load	   in	   blood,	   while	   the	   gag	   gene	   immunization	   was	  
associated	  with	  reduced	   lesion	  formation.	   Inclusion	  of	   IFN-­‐γ	  plasmid	   in	  the	   immunization	  mixture	  did	  not	  
enhance	   either	   humoral	   or	   cell-­‐mediated	   immune	   responses	   or	   protective	   effects,	   suggesting	   that	   this	  
cytokine	  was	  not	  a	  good	  mucosal	  molecular	  adjuvant	  for	  SRLV.	  
In	   the	   present	   study,	   we	   examined	   the	   effect	   of	   immunizing	   with	   VMV	   genes	   encoding	   the	   p55gag	  
precursor,	  gp150env	  precursor	  or	  a	  combination	  of	  these	  using	  PMED	  to	  prime	  and	  boost,	  and	  recombinant	  
modified	   vaccinia	   Ankara	   (MVA)	   to	   provide	   a	   protein	   boost.	  We	   also	   investigated	  whether	   including	   the	  
IFN-­‐γ	  gene	  (ifn)	  would	  enhance	  any	  protective	  effect	  when	  delivered	  via	  the	  skin.	  
2.	  Materials	  and	  methods	  
2.1.	  Sheep	  for	  vaccination	  experiments	  
One-­‐	  to	  six-­‐year	  old	  Lleyn	  sheep	  (females	  and	  castrated	  males)	  were	  obtained	  from	  a	  VMV-­‐free	  accredited	  
flock.	   Prior	   to	   immunization,	   absence	   of	   VMV	   was	   confirmed	   by	   commercially	   available	   ELISA	   (Elitest	  
MVV/CAEV,	  Hyphen	  Biomed)	  following	  the	  manufacturer’s	   instructions	  and	  by	  real-­‐time	  PCR	  as	  described	  
below.	   The	   animal	   experiments	  were	   performed	   at	   three	   European	   centres	   in	   accordance	  with	   national	  
regulations	  and	  institutional	  guidelines.	  
2.2.	  Viruses	  and	  plasmids	  
VMV	  strain	  EV1	  [25]	  was	  grown	  and	  titred	  as	  described	  previously	  [26].	  The	  same	  stock	  of	  virus	  was	  used	  to	  
challenge	   sheep	   in	   all	   three	   centres	   as	   described	   previously	   [24].	   Recombinant	   modified	   vaccinia	   virus	  
Ankara	  (MVA)	  expressing	  either	  the	  gag	  p55	  or	  the	  env	  gp150	  genes	  of	  VMV	  EV1	  or	  beta-­‐galactosidase	  (for	  
control	   immunization,	   MVA-­‐pSC11)	   were	   described	   previously	   [27]	   and	   [24].	   Recombinant	   MVAs	   were	  
named	  MVA-­‐gag	  and	  MVA-­‐env,	  respectively.	  MVA-­‐gag	  and	  MVA-­‐env	  were	  shown	  to	  express	  GAG	  and	  ENV,	  
respectively	  by	  Western	  blot	  using	  anti-­‐GAG	  and	  anti-­‐SU	  ENV	  specific	  rabbit	  sera	  (data	  not	  shown	  and	  [27]).	  
For	  injection,	  recombinant	  MVAs	  were	  purified	  over	  a	  sucrose	  cushion	  and	  then	  a	  sucrose	  gradient	  before	  
they	  were	  pelleted	  and	  re-­‐suspended	  in	  1	  mM	  Tris–HCl	  pH	  9.0.	  Virus	  was	  stored	  in	  aliquots	  at	  −80	  °C	  and	  an	  
aliquot	  used	   to	  determine	   titre.	  Virus	  was	  diluted	   in	  PBS	   for	   administration	   to	  animals,	   and	  108	  pfu	  was	  
given	  per	  animal	  subcutaneously.	  
Plasmids	   used	   for	   immunizations	   in	   this	   study	   were	   derivates	   of	   pN3-­‐EGFP	   (Clontech	   Laboratories,	   Inc.)	  
from	  which	  the	  EGFP	  gene	  was	  removed	  to	  generate	  plasmid	  pN3	  as	  described	  [24].	  This	  was	  used	  as	  the	  
control	  empty	  plasmid	  with	  no	  expressed	  gene	   in	   immunizations	  as	  well	  as	  the	  parental	  plasmid	  to	  make	  
pN3-­‐gag,	   pN3-­‐env	   and	   pN3-­‐ifn	   with	   the	   VMV	   gagp55	   and	   envgp150	   genes	   and	   the	   ovine	   ifn-­‐γ	   gene,	  
respectively.	  Expression	  of	  p55	  GAG	  and	  gp150	  ENV	  was	  determined	  by	  RT-­‐PCR	  and	  Western	  blotting	  (data	  
not	  shown)	  and	  [27].	  Expression	  of	  IFN-­‐γ	  in	  vitro	  was	  determined	  by	  RT-­‐PCR	  and	  ELISA	  [24].	  
2.3.	  Preparation	  of	  DNA-­‐coated	  gold	  particles	  for	  gene	  gun	  immunization	  
Gene	   gun	  parameters	   used	  were	   as	   previously	   described	   [28].	   In	   brief,	   22–25	  mg	  of	   1	   μm	  gold	  particles	  
(BioRad	  Laboratories	  Ltd.)	  were	  coated	  with	  DNA	  by	  addition	  of	  100	  μg	  plasmid	  DNA	  (1	  mg/ml	   in	  water),	  
100	  μl	   0.05	  M	   spermidine	   (Sigma–Aldrich	  Company	   Ltd.)	   and	  100	  μl	   1	  M	  CaCl2	   (Sigma–Aldrich	  Company	  
Ltd.),	   resulting	   in	  a	  DNA	   loading	   ratio	  of	  4	  μg/mg	  gold.	  The	  mixture	  was	  precipitated	   for	  10	  min	  at	   room	  
temperature	   and	   subsequently	   washed	   six	   times	   in	   1	   ml	   dehydrated	   99.9%	   (v/v)	   ethanol	   (VWR	  
International	   Ltd.).	   The	  DNA/gold	   particles	  were	   then	   re-­‐suspended	   in	   2.4	  ml	   of	   ethanol	   containing	   0.05	  
mg/ml	  polyvinylpyrrolidone.	  Each	  cartridge,	  containing	  approximately	  1	  μg	  of	  plasmid	  DNA,	  was	  delivered	  
using	   the	   Helios	   Gene	   gun	   system	   (BioRad	   Laboratories	   Ltd.).	   The	   gene	   gun	   discharge	   pressure	   used	   to	  
propel	  the	  DNA-­‐coated	  gold	  particles	  into	  the	  dermal–epidermal	  junction	  was	  500	  psi.	  
2.4.	  Expression	  and	  purification	  of	  recombinant	  GAG	  proteins	  
Plasmid	  clones	  of	  VMV	  strain	  EV1	  gag	  p25	  and	  p17	  (in	  pRSET	  plasmids)	  have	  been	  described	  previously	  [29].	  
Recombinant	  p25	  and	  p17	  and	  mock	  preparations	  were	  produced	  as	  previously	  described	  [24].	  
2.5.	  Experimental	  design	  
2.5.1.	  Immunization	  
The	   immunization	  groups	  and	   immunogens	  used	  are	  shown	   in	  Table	  1	  and	   the	  experimental	  design	   time	  
points	  are	  given	  in	  Fig.	  1.	  Groups	  and	  the	  plasmids	  that	  were	  administered	  were	  as	  follows:	  gag	  (n	  =	  8)	  –	  
pN3-­‐gag	  and	  pN3;	  gag-­‐ifn	  (n	  =	  8)	  –	  pN3-­‐gag	  and	  pN3-­‐ifn;	  env	  (n	  =	  8)	  –	  pN3-­‐env	  and	  pN3;	  env-­‐ifn	  (n	  =	  8)	  –	  
pN3-­‐env	  and	  pN3-­‐ifn;	  gag-­‐env	  (n	  =	  10)	  –	  pN3-­‐gag,	  pN3-­‐env	  and	  pN3;	  gag-­‐env-­‐ifn	  (n	  =	  10)	  –	  pN3-­‐gag,	  pN3-­‐
env	  and	  pN3-­‐ifn;	  control	  (n	  =	  22)	  –	  pN3.	  All	  experimental	  groups	  received	  a	  total	  of	  30	  μg	  plasmid	  at	  weeks	  
0	  and	  4,	  made	  up	  of	  10	  μg	  of	  each	  VMV	  or	  IFN-­‐γ	  gene	  plasmid	  and	  pN3.	  The	  control	  group	  received	  30	  μg	  
pN3.	  Sheep	  were	  boosted	  with	  108	  pfu	  recombinant	  MVA	  subcutaneously	  at	  week	  10.	  Groups	  gag	  and	  gag-­‐
ifn	  were	  given	  MVA-­‐gag	  and	  MVA-­‐pSC11;	  env	  and	  env-­‐ifn	  were	  given	  MVA-­‐env	  and	  MVA-­‐pSC11;	  gag-­‐env	  
and	  gag-­‐env-­‐ifn	  were	  given	  MVA-­‐gag	  and	  MVA-­‐env	  (108	  pfu	  each	  virus).	  The	  control	  group	  received	  MVA-­‐
pSC11.	  
	  	  	  	  
	  
	  	  	  	  Fig.	  1.	  	  
	  
Experimental	  design.	  The	  times	  of	  epidermal	  immunization	  with	  plasmid	  DNA	  (pDNA),	  subcutaneous	  injection	  with	  recombinant	  MVA	  (rMVA),	  and	  
intra-­‐tracheal	  challenge	  with	  VMV	  are	  shown.	  Animals	  were	  bled	  before	  immunization	  (priming	  at	  week	  0);	  after	  plasmid	  DNA	  immunization	  (week	  
7);	  after	  recombinant	  MVA	  boost	  and	  before	  challenge	  (week	  12);	  and	  after	  challenge	  (weeks	  16,	  20	  and	  24).	  Animals	  were	  slaughtered	  at	  week	  24–
25	  and	  tissue	  samples	  taken.	  
	  The	  immunizations	  were	  performed	  at	  three	  different	   laboratories	  as	  follows:	  Laboratory	  1	  –	  control,	  gag	  
and	  gag-­‐ifn;	  Laboratory	  2	  –	  control,	  env	  and	  env-­‐ifn;	  and	  Laboratory	  3	  –	  control,	  gag-­‐env	  and	  gag-­‐env-­‐ifn.	  
2.5.2.	  VMV	  challenge	  
	  
Challenge	  was	  performed	  12	  weeks	  post-­‐priming	  by	  injection	  of	  1	  ×	  103	  TCID50	  VMV	  EV1	  in	  1	  ml	  of	  PBS	  via	  
the	  intra-­‐tracheal	  route	  as	  described	  previously	  [30].	  
2.5.3.	  Sampling	  
	  
Blood	  samples	  were	  taken	  before	  the	  start	  of	  immunization	  (up	  to	  2	  weeks	  before	  priming,	  which	  was	  done	  
at	   week	   0),	   after	   DNA	   priming	   and	   boosting	   (week	   7),	   after	   recombinant	   MVA	   boosting	   but	   before	  
challenge	  (week	  12),	  and	  after	  VMV	  challenge	  (weeks	  16,	  20	  and	  24	  i.e.	  weeks	  4,	  8	  and	  12	  post-­‐challenge).	  
Sheep	  were	  euthanased	  and	  necropsied	  24–25	  weeks	  after	  the	  start	  of	  the	  experiment	  (12–13	  weeks	  post-­‐
challenge)	  and	  lung	  and	  mediastinal	  lymph	  node	  samples	  taken.	  
2.6.	  Measurement	  of	  anti-­‐VMV	  antibodies	  in	  serum	  
	  
Serum	  was	   taken	   from	   clotted	   blood,	   stored	   at	   −20	   °C	   and	   used	   to	  measure	   anti-­‐VMV	   antibodies	   in	   an	  
indirect	   ELISA	   using	  whole	   VMV	   antigen	   as	   previously	   described	   [24].	   The	   reciprocal	   of	   the	   last	   positive	  
serum	   dilution	   was	   taken	   as	   the	   titre	   of	   the	   antibody	   and	   the	   titre	   was	   expressed	   as	   log2(titre/50)	   i.e.	  
negative	  sera	  were	  given	  a	  value	  of	  0	  and	  titres	  of	  100,	  200,	  etc.,	  were	  assigned	  values	  of	  1,	  2	  and	  so	  on.	  
Untransformed	  titres	  were	  analysed	  statistically.	  
	  
For	  Western	   blotting,	   100	   μl	   of	   virus	   antigen	   prepared	   as	   described	   above	  were	   boiled	  with	   100	   μl	   2	   ×	  
Laemmli	  sample	  buffer	  (125	  mM	  Tris	  buffer	  with	  5%	  mercaptoethanol,	  2%	  SDS,	  pH	  6.8),	  applied	  to	  a	  4.5%	  
stacking	   gel	   and	   a	   10–16%	   gradient	   separation	   gel	   and	   blotted	   onto	   a	   transfer	   membrane	   following	  
electrophoresis.	   Transfer	   was	   carried	   out	   at	   4	   °C	   for	   120	   min	   in	   25	   mM	   Tris–glycine	   buffer,	   pH	   8.8,	  
containing	  20%	  methanol,	  at	  100	  V	  and	  250	  mA.	  After	  the	  transfer,	  the	  membrane	  was	  blocked	  for	  1	  h	  at	  
room	  temperature	  with	  0.1	  M	  Tris–HCl-­‐buffered	  saline,	  pH	  7.8,	  containing	  0.5%	  Tween	  20	  and	  2%	  low	  fat	  
milk	  powder.	   The	   serum	  and	  conjugate	  was	  diluted	   in	  0.1	  M	  Tris–HCl-­‐buffered	   saline,	  pH	  7.8,	   containing	  
0.1%	  Tween	  20	  (TBS-­‐T)	  and	  1%	  low	  fat	  milk	  powder.	  After	  blocking,	  the	  membrane	  was	  cut	  into	  strips	  and	  
incubated	  with	  serum	  samples	  diluted	  1:500	  overnight	  at	  4	  °C	  on	  a	  roller.	  Rabbit	  anti-­‐goat	  IgG	  conjugated	  
to	   alkaline	   phosphatase	  was	   used	   at	   a	   dilution	   of	   1:5000	   for	   1	   h	   at	   room	   temperature.	   The	   blots	   were	  
washed	  extensively	   in	  TBS-­‐T	  between	  each	  step.	  The	  blots	  were	  developed	  with	  NBT/BCIP	  diluted	  1:50	  in	  
AP	  buffer	  (100	  mM	  Tris,	  100	  mM	  NaCl,	  5	  mM	  MgCl2	  pH	  9.5).	  Prestained	  molecular	  markers	  were	  used	  in	  
the	  immunoblotting.	  
	  
Neutralization	   tests	   were	   performed	   as	   described	   previously	   [24].	   Neutralization	   titres	   of	   the	   sera	  were	  
calculated	  as	  the	  reciprocal	  of	  the	  serum	  dilution	  that	  caused	  complete	  neutralization	  in	  50%	  of	  inoculated	  
cultures.	  
2.7.	  Measurement	  of	  anti-­‐VMV	  T	  cell	  reactivity	  
	  
Blood	  was	  collected	  into	  heparin	  (10	  U/ml	  final)	  and	  peripheral	  blood	  mononuclear	  cells	  prepared	  by	  buffy	  
coat	  and	  Ficoll-­‐Metrizoate	  gradients,	   then	   suspended	   in	  RPMI-­‐1640	  medium	  with	  25	  mM	  HEPES	   (Sigma–
Aldrich	   Company	   Ltd.),	   supplemented	   with	   2	  mM	   l-­‐glutamine,	   50	   μM	   beta-­‐mercaptoethanol,	   antibiotics	  
(100	  U	  penicillin	  and	  100	  μg	  streptomycin/ml),	  2.5	  μg	  amphotericin	  B/ml	  and	  10%	  foetal	  calf	  serum	  (FCS)	  
(10%	   RPMI)	   [31].	   T	   cell	   proliferation,	   cytotoxicity,	   and	   IFN-­‐γ	   production	   were	   measured	   as	   described	  
previously	  [31]	  and	  [24].	  The	  T	  cell	  proliferation	  stimulation	  index	  (SI)	  for	  each	  antigen	  was	  calculated	  using	  
the	   formula	   SI	   =	   cpm	   with	   antigen/cpm	   with	   mock	   antigen.	   Results	   were	   analysed	   using	   the	   median	  
stimulation	  index	  of	  the	  antigen	  dilutions.	  For	  the	  CTL	  assay,	  animals	  were	  deemed	  to	  show	  the	  presence	  of	  
precursor	  CTL	  if	  the	  percentage	  specific	  51Cr	  release	  from	  VMV	  infected	  minus	  mock	  infected	  autologous	  
cells	  was	  >10%	  above	  that	  from	  heterologous	  infected	  minus	  mock	  infected	  cells	  [31],	  in	  which	  the	  killing	  of	  
mock	  infected	  and	  heterologous	  cells	  was	   less	  than	  10%.	  The	  frequency	  of	  CTL	  positive	  animals	  was	  used	  
for	  analysis	  of	  results.	  
	  
The	   results	  of	   the	   real-­‐time	  RT-­‐PCR	  assays	   for	   IFN-­‐γ	  RNA	  expression	  were	   taken	  as	  Ct	  values	  where	  Ct	   is	  
defined	   as	   the	   threshold	   cycle	   of	   the	   PCR	   at	   which	   amplified	   product	   was	   first	   detected.	   For	   analysis,	  
cytokine	   levels	  were	   normalised	   to	   glyceraldehyde	   3-­‐phosphate	   dehydrogenase	   (GAPDH)	   levels.	   Analysis	  
was	   performed	   using	   the	   mathematical	   model	   described	   by	   Pfaffl	   [32].	   Relative	   quantification	   of	   IFN-­‐γ	  
target	   gene	   transcript	  was	  made	   in	   comparison	   to	  GAPDH	   reference	   gene	   transcript	   using	   the	   equation:	  
ratio	  =	   (Etarget)Ct	   target(control	  −	   sample)/(Eref)Ct	   ref(control	  –	   sample)	  where	  Etarget	  and	  Eref	  are	   the	  
real-­‐time	  PCR	  efficiencies	  of	  IFN-­‐γ	  and	  GAPDH	  gene	  PCRs,	  respectively.	  Due	  to	  technical	  limitations	  samples	  
from	   sheep	   immunized	   with	   gag-­‐env	   or	   gag-­‐env-­‐ifn	   that	   were	   stimulated	   with	   whole	   virus	   were	   not	  
analysed.	  
2.8.	  Measurement	  of	  proviral	  load	  
	  
Provirus	  DNA	  loads	  in	  blood	  and	  lung	  and	  mediastinal	  lymph	  node	  tissue	  were	  measured	  by	  real-­‐time	  PCR	  
as	  described	  previously	  [24].	  The	  results	  are	  expressed	  as	  mean	  copy	  number	  per	  microgram	  of	  template	  
DNA.	  
2.9.	  Determination	  of	  pathological	  changes	  
	  
Lungs	   were	   removed	   aseptically	   and	   samples	   taken	   from	   four	   different	   lung	   lobes	   [the	   right	   accessory	  
(cranial)	   lobe,	  the	  right	  apical	  (medial)	   lobe,	  the	  right	  caudal	   lobe	  and	  the	  left	  cardiac	  (cranial)	   lung	  lobe)]	  
and	   mediastinal	   lymph	   node,	   and	   subjected	   to	   histological	   analysis	   as	   described	   previously	   [24].	  
Pathological	   changes	   typical	   of	   VMV	   infection	   in	   the	   lung	  were	   scored	   as	   follows:	   in	   the	   lung,	   lymphoid	  
follicle	  hyperplasia	  and	  interstitial	  pneumonia	  as	  well	  as	  bronchiole-­‐associated	  lymphoid	  tissue	  hyperplasia,	  
perivascular	   infiltrates,	   congestion	   and	   oedema	   were	   scored	   on	   a	   scale	   of	   0–4;	   and	   in	   the	   mediastinal	  
lymph	  node,	  lymphoid	  follicle	  reactivity	  and	  cortical	  hyperplasia	  were	  scored	  on	  a	  scale	  of	  0–2.	  The	  mean	  of	  
all	  scores	  was	  calculated	  for	  each	  animal.	  
2.10.	  Immunochemistry	  
	  
Immunostaining	   for	  VMV	  p25	  was	  performed	  on	   tissues	  obtained	   from	  the	  right	  caudal	   lung	   lobe.	  Tissue	  
samples	   were	   collected	   and	   fixed	   in	   Bouin	   solution	   for	   6–8	   h,	   followed	   by	   several	   70%	   alcohol	   washes.	  
Samples	  were	  paraffin-­‐embedded	  and	  4	  μm	  sections	  were	  stained	  by	  immunohistochemical	  labelling	  using	  
Envision	  PlusTM	  peroxidase®	  method	  (Dako	  Cytomation).	  Antigen	  retrieval	  was	  carried	  out	  in	  citrate	  buffer	  
pH	  6,	   for	  3	  min	   in	  a	  pressure	  cooker	  and	  cooling	   in	  distilled	  water	  at	  room	  temperature	  prior	  to	  blocking	  
endogenous	   peroxidase	  with	   3%	  hydrogen	  peroxide.	   Protein	   blocking	   (Dako	  Cytomation)	  was	   performed	  
for	  15	  min	  at	  room	  temperature	  followed	  by	  incubation	  for	  1	  h	  at	  37	  °C	  with	  VPM70	  (primary	  monoclonal	  
antibody	   against	   VMV	   p25	   protein).	   After	   washing	   in	   TBS	   buffer,	   the	   sections	   were	   incubated	   with	  
Envision™	  mouse	  peroxidase	  for	  30	  min	  at	  room	  temperature,	  washed	  in	  TBS	  buffer	  and	  incubated	  with	  3-­‐
3-­‐diaminobenzidine	  (DAB;	  Dako	  Cytomation)	  for	  10	  min	  as	  substrate	  for	  the	  peroxidase	  reaction.	  The	  slides	  
were	  rinsed,	  counterstained	  with	  hematoxylin	  and	  mounted	  under	  DPX.	  Replacement	  of	  primary	  antibody	  
by	  TBS	  was	  used	  for	  the	  negative	  control	  sections.	  
2.11.	  Statistical	  analysis	  
	  
Data	   analysis	   consisted	   of	   comparing	   specific	   pairwise	   groups	   at	   particular	   time	   points.	   If	   possible,	   data	  
were	   transformed	   to	  give	  a	  normal	  distribution	   then	  analysed	  with	  a	   standard	  2-­‐sample	  Student’s	   t-­‐test.	  
Where	  data	   could	  not	  be	  normalised	   through	   transformation	   the	  non-­‐parametric	  equivalent	  –	   the	  Mann	  
Whitney	  test	  –	  was	  used.	  Frequency	  data	  were	  analysed	  using	  Fisher	  exact	  tests.	  In	  all	  cases	  a	  p	  <	  0.05	  was	  
taken	  to	  indicate	  statistical	  significance.	  
3.	  Results	  
3.1.	  Induction	  of	  antibody	  responses	  
	  
The	  presence	  of	  antibody	  was	  tested	  using	  a	  whole	  virus	  ELISA	  with	  an	  anti-­‐sheep	  IgG	  detection	  step	  (Fig.	  
2).	   There	   was	   no	   evidence	   of	   antibody	   induction	   by	   the	   plasmid	   immunization	   (week	   7)	   in	   any	   of	   the	  
groups.	   However,	   after	   the	  MVA	   boost	   the	   gag,	   gag-­‐env	   and	   gag-­‐env-­‐ifn	   groups	   all	   showed	   significantly	  
increased	  antibody	  levels	  compared	  to	  the	  control	  group	  (p	  <	  0.001;	  p	  =	  0.002;	  p	  =	  0.033,	  respectively)	  (	  Fig.	  
2A).	  There	  was	  no	  statistically	  significant	  effect	  of	  immunization	  with	  ifn-­‐γ.	  When	  the	  gag	  and	  gag-­‐ifn,	  and	  
gag-­‐env	  and	  gag-­‐env-­‐ifn	  groups	  were	  pooled	  induction	  of	  antibody	  was	  seen	  in	  both	  pooled	  groups	  at	  week	  
12	  (p	  =	  0.006).	  The	  antibody	  response	  compared	  to	  controls	  was	  increased	  after	  challenge	  in	  the	  gag-­‐env	  
and	  gag-­‐env-­‐ifn	  groups	  at	  week	  4	  post-­‐infection	  only	  (week	  16	  after	   immunization)	  (p	  =	  0.032;	  p	  =	  0.047,	  
respectively,	  pooled	  groups	  p	  =	  0.013)	  (	  Fig.	  2B).	  Following	  this	  time	  point	  all	  groups	  showed	  similar	  titres	  of	  
antibody.	  The	  antibodies	  were	  of	  the	  IgG1	  subclass,	  with	  no	  IgG2	  antibody	  responses	  being	  observed	  (data	  
not	  shown).	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  Fig.	  2.	  	  
	  	  	  	  Antibody	  titre	  determined	  using	  whole	  virus	  ELISA.	  Serial	  two-­‐fold	  dilutions	  of	  sera	  from	  sheep	  were	  tested	  on	  a	  whole	  VMV	  ELISA	  before	  and	  
after	  challenge	  with	  VMV.	  The	  results	  are	  given	  as	  the	  mean	  titre	  (log2[titre/50])	  ±	  standard	  error	  of	  the	  group.	  Time	  post	   immunization:	  (A)	  –	  ▵	  
week	  0;	  □	  week	  7;	  ○	  week	  12;	  (B)	  –	  ▴	  week	  16;	  ■	  week	  20;	  ●	  week	  24.	  (*)	  Titre	  greater	  than	  the	  control	  group	  (p	  <	  0.05,	  groups	  gag,	  gag-­‐env	  and	  
gag-­‐env-­‐ifn	  week	  12,	  and	  gag-­‐env	  and	  gag-­‐env-­‐ifn	  week	  16)	  using	  Mann–Whitney	  tests.	  
	  
Anti-­‐ENV	  antibodies	  were	  detectable	  by	  Western	  blotting	  and	  the	  number	  of	  positive	  animals	  scored.	  These	  
antibodies	  were	   found	   in	  all	  animals	   receiving	   the	  env	   immunogen	   (env,	  env-­‐ifn,	  gag-­‐env,	  gag-­‐env-­‐ifn)	  at	  
week	  16	  but	  not	  in	  the	  animals	  that	  received	  gag	  or	  gag-­‐ifn	  until	  week	  20	  (data	  not	  shown).	  The	  majority	  of	  
animals	   were	   anti-­‐ENV	   antibody	   positive	   by	   week	   12	   after	   challenge	   (week	   24,	   data	   not	   shown).	   No	  
neutralizing	  antibody	  was	  detectable	  in	  any	  sample	  (data	  not	  shown).	  
3.2.	  T	  lymphocyte	  responses	  
3.2.1.	  Cytotoxic	  T	  lymphocytes	  
	  
At	   week	   7,	   following	   plasmid	   immunization,	   only	   the	   gag-­‐env-­‐ifn	   group	   showed	   statistically	   significantly	  
increased	  numbers	  of	  CTL	  positive	  sheep	  compared	  to	  controls	  (p	  =	  0.007)	  (	  Fig.	  3B),	  though	  the	  env	  group	  
showed	  a	  similar	  trend	  (p	  =	  0.052).	  However,	  this	  was	  not	  maintained	  after	  MVA	  immunization	  (week	  12)	  (p	  
=	  0.648	  and	  p	  =	  0.645,	  respectively).	  After	  challenge,	  more	  sheep	  became	  CTL	  positive	  but	  again	  few	  groups	  
were	  significantly	  different	  to	  the	  control	  group:	  the	  gag-­‐env	  group	  at	  week	  20	  (p	  =	  0.005)	  and	  env	  group	  at	  
week	  24	   (p	  =	  0.032)	   (	  Fig.	  3E	  and	  F).	   Immunization	  with	  the	   ifn	  gene	  did	  not	   increase	  the	  number	  of	  CTL	  
positive	  animals	  after	  challenge,	  so	  groups	  were	  pooled	  for	  further	  analysis.	  The	  CTL	  frequencies	  in	  the	  gag	  
and	  gag-­‐ifn	  combined	  groups	  were	  not	  statistically	  significantly	  different	  from	  controls.	  The	  combined	  env	  
and	  env-­‐ifn	  groups	  gave	  significantly	  higher	  frequencies	  compared	  to	  controls	  at	  week	  24	  (p	  =	  0.020).	  The	  
combined	  gag-­‐env	  and	  gag-­‐env-­‐ifn	  groups	  were	  significantly	  higher	   than	  controls	  at	  week	  20	   (p	  =	  0.012).	  
When	   animals	   that	   received	   the	   gag	   immunogen	   (gag,	   gag-­‐ifn,	   gag-­‐env,	   gag-­‐env-­‐ifn)	   were	   compared	   to	  
controls,	   the	   CTL	   frequencies	   were	   not	   significantly	   different.	   In	   contrast,	   the	   frequencies	   observed	   in	  
animals	   receiving	   the	   env	   immunogen	   (env,	   env-­‐ifn,	   gag-­‐env,	   gag-­‐env-­‐ifn)	   were	   significantly	   higher	   than	  
controls	  at	  week	  7	  (p	  =	  0.041),	  week	  20	  (p	  =	  0.028)	  and	  week	  24	  (p	  =	  0.047).	  
	  
	  	  	  	  Fig.	  3.	  	  
	  	  	  	  CTL	  responses.	  The	  proportion	  of	  CTL	  positive	  animals	   in	  each	   immunization	  group	  is	  shown	  at	  the	  different	  time	  points.	   (*)	  Proportion	  of	  CTL	  
positive	  animals	  greater	  than	  the	  control	  group	  (before	  challenge,	  gag-­‐env-­‐ifn	  group	  week	  7,	  p	  =	  0.007;	  after	  challenge,	  gag-­‐env	  week	  20,	  p	  =	  0.005	  
and	  env	  week	  24,	  p	  =	  0.032)	  using	  a	  Fisher’s	  Exact	  test.	  
	  
Within	  groups,	  the	  control	  group	  did	  not	  differ	  from	  time	  0	  at	  any	  time	  point.	  The	  pooled	  env	  with	  env-­‐ifn	  
and	  gag-­‐env	  with	  gag-­‐env-­‐ifn	  groups	  showed	  statistically	  significant	  increases	  in	  the	  number	  of	  CTL	  positive	  
animals	  after	  plasmid	  vaccination	  (p	  =	  0.043	  and	  0.047,	  respectively)	  with	  increasing	  statistical	  significance	  
after	  MVA	  boost	   compared	   to	  week	  0	   (p	  =	  0.042	  and	  0.008,	   respectively).	  After	   challenge,	   there	  was	  no	  
further	   increase	   in	   the	  number	  of	  CTL	  positive	  sheep	  compared	   to	  week	  12	   (after	  MVA	   immunization)	   in	  
groups	   immunized	   with	   either	   gag	   or	   env.	   The	   results	   show	   that	   immunization	   had	   been	   successful	   at	  
inducing	  CTL	  responses,	  although	  these	  responses	  were	  not	  strong.	  
3.2.2.	  T	  lymphocyte	  proliferative	  responses	  
	  
Immunization	  with	  plasmid	  expressing	  ovine	  IFN-­‐γ	  had	  no	  effect	  on	  the	  magnitude	  of	  the	  T	  cell	  proliferative	  
response	  of	  PBMC	  to	  any	  of	  the	  three	  antigens	  used	  (EV1,	  p25	  gag	  and	  p17	  gag).	  The	  immunogen	  and	  the	  
respective	  immunogen	  +	  ifn	  groups	  were	  therefore	  pooled	  for	  analysis.	  No	  increased	  proliferative	  response	  
was	  seen	  with	  whole	  virus	  EV1	  antigen	  after	  plasmid	   immunization	   (week	  7,	  Fig.	  4A).	  Following	  the	  MVA	  
boost	   at	   week	   10,	   transiently	   increased	   proliferative	   responses	   were	   seen	   at	   weeks	   12	   and	   16	   (after	  
challenge)	  in	  the	  gag	  and	  gag-­‐ifn	  groups	  combined	  and	  the	  gag-­‐env	  and	  gag-­‐env-­‐ifn	  groups	  combined	  (p	  =	  
0.022	  and	  0.009,	  respectively	  for	  gag	  and	  p	  =	  0.032	  and	  0002,	  respectively	  for	  gag-­‐env)	  and	  only	  at	  week	  12	  
in	  the	  env	  and	  env-­‐ifn	  groups	  combined	  (p	  =	  0.003)	  (	  Fig.	  4A).	  
	  
	  	  	  	  Fig.	  4.	  	  
	  	  	  	  T	  cell	  proliferation	  responses.	  The	  degree	  of	  T	  cell	  proliferative	  responses	  is	  shown.	  Results	  are	  expressed	  as	  the	  median	  of	  the	  group’s	  median	  
stimulation	  index	  for	  each	  antigen	  against	  time.	  Antigen	  used:	  (A)	  EV1;	  (B)	  p25;	  (C)	  p17.	  Groups:	  ■	  control;	  ●	  gag	  +	  gag-­‐ifn;	  ▴	  env	  +	  env-­‐ifn;	  ♦	  gag-­‐
env	  +	  gag-­‐env-­‐ifn.	  Due	  to	  technical	  limitations,	  the	  gag-­‐env	  and	  gag-­‐env-­‐ifn	  groups	  do	  not	  have	  data	  for	  EV1	  antigen.	  (*)	  Significantly	  greater	  than	  
controls;	  (§)	  Significantly	  lower	  than	  controls	  p	  <	  0.05.	  Analysis	  by	  Mann–Whitney	  test	  of	  median	  stimulation	  indices.	  
	  
Stimulation	  with	  p25	  or	  p17	  GAG	  antigens,	   did	  not	   induce	   significantly	   greater	  proliferative	   responses	   in	  
env	  and	  env-­‐ifn	  groups	  compared	  to	  controls	  before	  challenge	  as	  expected	  (week	  7	  and	  12,	  Fig.	  4B),	  and	  
also	   after	   challenge	   (weeks	   16,	   20	   and	   24).	   Indeed,	   depressed	   responses	   were	   seen	   to	   p25	   GAG	   after	  
challenge	   in	   the	   pooled	   env	   and	   env-­‐ifn	   groups	   (p	   =	   0.001,	   0.005	   and	   0.011	   at	   week	   16,	   20	   and	   24,	  
respectively)	   (	   Fig.	   4B)	   and	   to	   p17	   GAG	   immediately	   after	   challenge	   in	   the	   single	   env	   group	   (p	   =	   0.031)	  
(week	  16,	  data	  not	   shown).	   In	   contrast,	   statistically	   significant	   increases	   in	  T	   cell	  proliferation	   to	   the	  p25	  
antigen	  were	  found	  with	  the	  combined	  gag	  and	  gag-­‐ifn	  groups	  and	  the	  combined	  gag-­‐env	  and	  gag-­‐env-­‐ifn	  
groups	  before	  challenge	  at	  week	  7	  and	  week	  12	  (p	  <	  0.000	  and	  p	  =	  0.05	  for	  gag	  and	  p	  =	  0.008	  and	  0.014	  for	  
gag-­‐env	   at	   week	   7	   and	   12,	   respectively,	   Fig.	   4B).	   However,	   these	   increased	   proliferative	   responses	  
compared	   with	   controls	   were	   not	   maintained	   after	   challenge.	   When	   p17	   was	   used	   as	   the	   antigen,	   the	  
individual	   (data	   not	   shown)	   and	   combined	   gag-­‐env	   and	   gag-­‐env-­‐ifn	   groups	   showed	   significantly	   elevated	  
responses	  from	  week	  7	  onwards	  (p	  <	  0.02	  for	  all	  time	  points)	  (	  Fig.	  4C).	  In	  contrast,	  the	  combined	  gag	  and	  
gag-­‐ifn	  groups	  and	  combined	  env	  and	  env-­‐ifn	  groups	  did	  not	  show	  greater	  proliferative	  responses	  to	  p17	  
compared	  with	  controls	  at	  any	  time	  point.	  
3.3.	  IFN-­‐γ	  responses	  
	  
IFN-­‐γ	  expression	  by	  PBMCs	   following	   stimulation	  with	  EV1,	  p25,	  or	  p17	  antigen	  was	   assessed	  during	   the	  
course	   of	   immunization	   and	   challenge.	   In	   general,	   very	   few	   animals	   showed	   significant	   IFN-­‐γ	   expression	  
using	  the	  EV1	  antigen	  (data	  not	  shown).	  The	  expression	  levels	  of	  IFN-­‐γ	  in	  PBMC	  in	  response	  to	  stimulation	  
with	   p25	   and	   p17	   prior	   to	   challenge	   were	   not	   significantly	   different	   from	   controls	   (data	   not	   shown).	  
Following	  challenge,	  there	  was	  a	  trend	  towards	  increased	  expression	  levels	  of	  IFN-­‐γ	  RNA	  in	  response	  to	  p25	  
in	  the	  combined	  env	  and	  env-­‐ifn	  groups	  at	  week	  16	  (p	  =	  0.072)	  and	  this	  was	  significantly	  increased	  at	  week	  
20	  (p	  =	  0.007,	  Fig.	  5A)	  but	  not	  week	  24	  (data	  not	  shown).	  An	  increase	  in	  IFN-­‐γ	  expression	  in	  response	  to	  p25	  
was	  seen	  in	  PBMC	  from	  gag-­‐env	  and	  gag-­‐env-­‐ifn	  immunized	  animals	  (p	  =	  0.034)	  at	  week	  16	  but	  this	  was	  not	  
seen	  at	  later	  time	  points.	  However,	  when	  all	  the	  groups	  which	  had	  been	  immunized	  with	  env	  were	  analysed	  
together	  there	  was	  a	  significant	  increase	  in	  IFN-­‐γ	  expression	  by	  PBMC	  in	  response	  to	  p25	  at	  both	  week	  16	  
(p	  =	  0.019)	  and	  week	  20	  (p	  =	  0.012)	  (	  Fig.	  5A)	  but	  not	  week	  24	  (data	  not	  shown).	  When	  p17	  was	  used	  as	  the	  
stimulating	   antigen	   the	   combined	   gag	   and	   gag-­‐ifn	   groups,	   env	   and	   env-­‐ifn	   and	   gag-­‐env	   and	   gag-­‐env-­‐ifn	  
groups	  were	  all	  similar	  to	  controls	  at	  week	  16	  (p	  =	  0.290;	  p	  =	  0.211;	  p	  =	  0.091,	  respectively)	  (	  Fig.	  5B).	  At	  
week	   20	   the	   env	   and	   env-­‐ifn	   groups	   combined	   showed	   significantly	   lower	   IFN-­‐γ	   expression	   levels	   than	  
controls	   (p	   =	   0.036).	   At	  week	   24,	   the	   env	   and	   env-­‐ifn	   groups	   combined	  were	  not	   significant	   different	   to	  
controls	  (data	  not	  shown).	  
	  
	  	  	  	  Fig.	  5.	  	  
	  	  	  	  IFN-­‐γ	  RNA	  expression	  levels	  in	  response	  to	  stimulation	  with	  GAG	  p25	  and	  p17.	  PBMC	  were	  cultured	  for	  4	  h	  with	  25	  μg	  antigen	  (A.	  p25;	  B.	  p17)	  or	  
mock	  antigen	  and	  cellular	  RNA	  prepared.	  IFN-­‐γ	  expression	  levels	  were	  normalised	  to	  GAPDH	  RNA	  expression	  and	  the	  normalised	  levels	  in	  different	  
groups	   compared	   to	   controls	   by	  Mann–Whitney	   test.	   (*)	   Significantly	   greater	   than	   controls;	   (§)	   significantly	   lower	   than	   controls,	   p	   <	   0.05.	   The	  
median	  expression	  ratios	  (E)	  of	  the	  groups	  are	  shown	  at	  weeks	  16	  and	  20	  (weeks	  4	  and	  8	  post-­‐challenge).	  
	  
3.4.	  Virus	  load	  
Provirus	  DNA	  load	  in	  blood	  and	  tissues	  (lung	  and	  mediastinal	  lymph	  node)	  was	  measured	  by	  real-­‐time	  PCR.	  
All	  PBMC	  samples	  were	  negative	  before	  challenge	  (data	  not	  shown).	  There	  was	  no	  effect	  of	  immunization	  
with	  the	  ifn	  gene.	  When	  the	  gag	  and	  gag-­‐ifn	  groups	  were	  pooled	  the	  blood	  proviral	  DNA	  load	  was	  reduced	  
in	  comparison	  to	  controls	  (p	  =	  0.048)	  (	  Fig.	  6A).	  The	  provirus	  load	  tended	  to	  be	  higher	  than	  controls	  in	  the	  
other	  immunized	  groups,	  but	  the	  values	  were	  not	  statistically	  different	  from	  controls	  either	  as	  single	  groups	  
or	  combined	  with	  the	  respective	  ifn	  groups	  (p	  >	  0.139).	  
	  
	  
	  	  	  	  Fig.	  6.	  	  
	  	  	  	  Proviral	   load	  after	   challenge	   in	  blood,	   lung	  and	  mediastinal	   lymph	  node.	  The	  proviral	  DNA,	  measured	  using	  a	  VMV	  p25	   specific	   real-­‐time	  PCR	  
assay,	  is	  shown.	  The	  results	  are	  expressed	  as	  mean	  copy	  number	  per	  μg	  extracted	  DNA	  ±	  standard	  error	  of	  the	  group.	  Blood	  samples	  were	  taken	  at	  
week	  16,	  20	  and	  24	  and	  the	  maximum	  copy	  number	  of	  the	  three	  measurements	  used	  as	  the	  value	  for	  the	  sheep.	  Blood	  data	  were	  transformed	  to	  
achieve	  normality	  (KS	  normality	  test)	  and	  equal	  variance	  (Levene’s	  test)	  and	  groups	  compared	  by	  a	  Student’s	  t-­‐test.	  The	  proviral	  DNA	  load	  in	  lung	  
sections	  and	  mediastinal	  lymph	  node	  was	  measured	  at	  week	  12–13	  post-­‐challenge	  (week	  24–25	  post	  immunization).	  The	  maximum	  copy	  number	  of	  
the	   four	   lung	  segments	  was	  used	  as	  the	  value	   for	   the	  animal.	  Analysis	  of	   the	   lung	  and	  mediastinal	   lymph	  node	  data	  was	  by	  Mann–Whitney	  test	  
since	  normality	  could	  not	  be	  achieved	  through	  data	   transformation.	   (A)	  Mean	  of	   the	  maximum	  blood	  viral	   load;	   (B)	  mean	  of	   the	  maximum	  lung	  
section	  load;	  (C)	  mean	  of	  the	  mediastinal	  lymph	  node	  proviral	  load.	  (§)	  Proviral	  load	  less	  than	  the	  control	  group	  (p	  <	  0.05,	  blood:	  pooled	  gag	  and	  
gag-­‐ifn	  groups;	  mediastinal	  lymph	  node:	  gag-­‐env).	  
	  
In	  the	  lung,	  no	  statistically	  significant	  differences	  in	  provirus	  DNA	  load	  were	  observed	  between	  controls	  and	  
immunized	  groups	  by	  PCR	  (p	  >	  0.396)	   (	  Fig.	  6B).	  Nearly	  all	   lung	  sections	  tested	  were	  positive	  for	  provirus	  
DNA	   by	   in	   situ	   hybridization	   (not	   shown).	   To	   obtain	   a	  measure	   of	   virus	   expression	   in	   lung	   tissues	   after	  
challenge,	   immunohistochemistry	   for	   p25	   was	   performed	   on	   the	   right	   caudal	   lung	   lobe	   taken	   at	   post-­‐
mortem.	  The	   frequency	  of	  positive	  p25	  staining	  reactions	   in	   the	  right	  caudal	   lung	   lobe	   in	   immunized	  and	  
control	   groups	   is	   shown	   in	   Table	   2.	   A	   significantly	   reduced	   p25	   expression	   was	   noted	   in	   the	   animals	  
receiving	  gag-­‐env	  and	  gag-­‐env-­‐ifn	   compared	   to	   controls	  when	   the	   two	   immunized	  groups	  were	  analysed	  
together	  (p	  =	  0.012).	  The	  frequency	  of	  samples	  positive	  for	  provirus	  DNA	  in	  this	  lung	  lobe	  also	  tended	  to	  be	  
lower	   in	   the	   gag-­‐env	   and	   gag-­‐env-­‐ifn	   groups	   compared	   to	   controls,	   though	   this	   difference	   was	   not	  
statistically	   significant.	   The	   frequency	   of	   positive	   p25	   staining	   observed	   in	   the	   groups	   receiving	   ifn	  
combined	  (9.5%)	  was	  significantly	  lower	  than	  that	  of	  the	  other	  groups	  combined	  (39.1%;	  p	  =	  0.040),	  though	  
the	  provirus	  load	  was	  not	  significantly	  different.	  
	  
	  	  	  	  	  
	  
The	  provirus	  load	  in	  the	  mediastinal	  lymph	  node	  was	  significantly	  reduced	  compared	  to	  controls	  in	  the	  gag-­‐
env	  group	  (p	  =	  0.046),	  but	  not	  in	  the	  other	  groups	  (p	  >	  0.278)	  (	  Fig.	  6C).	  
3.5.	  Pathology	  in	  tissues	  
	  
We	   determined	   the	   early	   (week	   12–13	   post-­‐infection)	   pathology	   scores	   after	   infection	   in	   control	   and	  
immunized	  animals.	  The	  scores	  of	   the	  groups	  are	  shown	   in	  Fig.	  7.	  No	  group	  showed	  protection	   from	  the	  
development	  of	   disease.	  However,	   the	   env-­‐ifn	   group	  had	  developed	  worse	  pathological	   lesions	   than	   the	  
control	  group	  by	  week	  12–13	  post-­‐infection	  (p	  =	  0.011).	  When	  the	  env	  and	  env-­‐ifn	  groups	  were	  combined	  
the	  pathology	  scores	  were	  significantly	  higher	  than	  controls	  (p	  =	  0.009).	  The	  gag	  and	  gag-­‐ifn	  combination	  
and	   gag-­‐env	   and	   gag-­‐env-­‐ifn	   pooled	   groups	  were	   not	   different	   from	   controls	   (p	   =	   0.307	   and	   p	   =	   0.537,	  
respectively).	   When	   the	   lesion	   scores	   were	   assigned	   into	   mild/absent	   (mean	   score	   ≤	   1.0)	   or	   severe	  
categories	   (mean	   score	   >	   1.0)	   the	   combined	   env	   and	   env-­‐ifn	   groups	   had	   a	   higher	   frequency	   of	   severe	  
lesions	   (10/16)	   compared	   to	   controls	   (5/22,	   p	   =	   0.020	   using	   Fisher’s	   exact	   test).	   The	   gag	   and	   gag-­‐ifn	  
combination	   and	   gag-­‐env	   and	   gag-­‐env-­‐ifn	   combination	   had	   frequencies	   of	   severe	   lesions	   that	   were	   not	  
different	  to	  controls	  (4/16,	  p	  =	  1.000	  and	  1/20,	  p	  =	  0.187,	  respectively).	  
	  
	  	  	  	  Fig.	  7.	  	  
	  	  	  	  Tissue	   pathology.	   Pathological	   changes	   in	   the	   lung	   and	  mediastinal	   lymph	   node	   were	   scored	   and	   the	   results	   expressed	   as	   the	   mean	   of	   the	  





In	  the	  present	  study	  PMED	  was	  used	  in	  conjunction	  with	  MVA	  to	  prime	  and	  boost	  sheep	  against	  VMV	  gag	  
and	  env	  genes.	  Gag	  and	  gag-­‐env	  (but	  not	  single	  env)	  genes	  induced	  elevated	  antibody	  responses	  by	  ELISA,	  
but	  these	  were	  transitory	  as	  by	  week	  24	  the	  levels	  were	  not	  different	  to	  controls.	  However,	  the	  response	  to	  
a	  combination	  of	  gag	  and	  env	  genes	  gave	  a	  more	  sustained	  response	  from	  week	  12	  to	  week	  16,	  compared	  
to	  the	  responses	  observed	  with	  single	  gag	  gene	  immunization.	  There	  was	  a	  delay	  in	  the	  anti-­‐ENV	  antibody	  
production	   in	   the	   pooled	   gag	   and	   gag-­‐ifn	   group	   compared	   to	   env	   immunized	   animals	   4	   weeks	   after	  
challenge.	   It	   is	  possible	   that	  gag	   immunization	   resulted	   in	   the	  antibody	   responses	  being	   focused	  on	  GAG	  
antigens,	  such	  that	  when	  virus	  was	  introduced	  antibody	  responses	  to	  ENV	  were	  competitively	  inhibited.	  No	  
delay	   in	   the	   appearance	   of	   anti-­‐env	   antibody	   responses	   was	   seen	   in	   animals	   that	   received	   the	   gag-­‐env	  
immunogen,	   arguably	  because	   the	  presence	  of	   env	   in	   the	   immunization	  mixture	  balanced	   that	  of	   gag	   to	  
prevent	  a	  predominant	  antibody	  response	  to	  gag.	  Alternatively,	  the	  lower	  provirus	  load	  observed	  in	  the	  gag	  
immunized	   animals	   may	   have	   caused	   delayed	   anti-­‐ENV	   antibody	   production.	   However,	   anti-­‐whole	   VMV	  
antibody	  responses	  were	  not	  delayed	  or	  diminished.	  
	  
The	  antibody	   levels	  obtained	  following	  PMED	   immunization	  were	  significantly	   lower	  than	  those	  observed	  
following	   immunization	  with	  the	  same	  immunogens	  administered	  via	  the	  respiratory	  tract	  [24].	  However,	  
since	  the	  antibody	  level	  of	  controls	  were	  similarly	  lower	  the	  effect	  is	  likely	  to	  be	  non-­‐specific.	  Neutralizing	  
antibodies	  were	   not	   induced	   by	   the	   PMED	   immunization	   protocol	   used	   here,	   as	  was	   the	   case	   following	  
mucosal	  immunization	  [24].	  
	  
T	   cell	   proliferative	   responses	   to	   VMV	   antigens	   following	   PMED	   immunization	   were	   examined	   to	   assess	  
activation	  of	   cell-­‐mediated	   immune	   responses.	   The	   relatively	   poor	  proliferative	   responses	  observed	  with	  
EV1	   antigen	  may	  have	   been	  due	   to	   the	   presence	   of	   low	   amounts	   of	  GAG	   and	   ENV	   antigens	   in	   the	   virus	  
preparation.	  As	  expected,	  the	  highest	  responses	  using	  p25	  or	  p17	  antigens	  were	  found	  in	  the	  gag	  and	  gag-­‐
env	   groups.	   The	   results	   indicate	   that	   DNA	   immunization	   with	   the	   full	   length	   p55	   gag	   precursor	   gene	  
induced	  not	  only	  expression	  of	  the	  mature	  GAG	  proteins	  in	  vivo	  but	  that	  the	  proteins	  were	  processed	  and	  
presented	  via	  an	  MHC	  class	  2	  pathway	  to	  T	  cells.	  
	  
The	  proliferative	  response	  to	  p25	  or	  p17	  antigens	  in	  animals	  immunized	  with	  env	  or	  env-­‐ifn	  was	  expected	  
to	  be	  similar	   to	  controls.	  The	  observation	   that	  both	  env	  and	  env-­‐ifn	  groups	  showed	  significantly	   lowered	  
responses	  compared	  to	  controls	  suggests	  that	  env	  immunization	  interferes	  with	  the	  normal	  T	  cell	  responses	  
to	   GAG	   expected	   after	   challenge.	   This	  was	   not	   observed	  when	   the	   same	   genes	  were	   used	   to	   immunize	  
sheep	   mucosally	   [24].	   However,	   recent	   studies	   on	   immune	   responses	   to	   HIV	   gag	   and	   env	   genes	   have	  
revealed	  an	   antigen-­‐specific	   suppressive	  effect	   of	   env	  on	  GAG-­‐specific	   T	   cell	   responses	   in	  mice	   [33].	   The	  
mechanism(s)	  underlying	  this	  effect	  of	  systemic	  env	  immunization	  is	  unknown.	  
	  
Increased	   frequencies	   of	   CTLs	   were	   found	   over	   the	   course	   of	   priming,	   boosting,	   and	   challenge	   with	   all	  
immunogens,	  but	  the	  responses	  were	  weak	  and	  transitory.	   Immunization	  using	  PMED	  has	  been	  shown	  to	  
induce	   CTLs	   in	   other	   virus	   infections,	   including	   lentiviruses	   [34],	   [35]	   and	   [36].	   Significant	   induction	   has	  
usually	  required	  the	  use	  of	  viral	  boosting	  vectors,	  numerous	  plasmid	  boosts	  or	  high	  plasmid	  doses.	  MVA	  is	  
often	  used	  as	  a	  viral	  vector	  to	  provide	  an	  efficient	  protein	  boost	  [37]	  and	  [38].	  However,	   in	  our	  study	  we	  
could	   not	   discern	   a	   significant	   boosting	   effect	   of	  MVA	   for	   CTLs.	   In	   contrast,	   MVA	   provided	   a	   boost	   for	  
antibody	  production	  in	  animals	  receiving	  gag	  or	  gag-­‐env	  genes,	  indicating	  that	  MVA	  does	  deliver	  a	  protein	  
boost	  in	  sheep.	  
	  
Despite	  the	  generally	  low	  level	  of	   immune	  priming	  and	  boosting	  achieved	  using	  PMED	  and	  MVA,	  provirus	  
DNA	  levels	  in	  animals	  that	  received	  the	  single	  gag	  immunogen	  were	  significantly	  decreased	  in	  blood	  though	  
similar	  to	  controls	  in	  the	  lungs.	  These	  results	  contrast	  with	  those	  obtained	  previously	  in	  animals	  immunized	  
mucosally	   with	   gag	   where	   the	   provirus	   loads	   in	   blood	   were	   not	   different	   to	   controls	   12	   weeks	   post-­‐
challenge	   [24].	   This	   may	   reflect	   compartmentalization	   of	   immune	   responses	   following	   mucosal	   and	  
systemic	  immunization.	  
	  
The	  provirus	  load	  in	  lung	  tissue	  in	  animals	  immunized	  with	  gag	  using	  PMED	  was	  not	  different	  to	  controls.	  In	  
contrast,	  mucosal	   immunization	  with	  gag	  resulted	   in	  significantly	  elevated	  provirus	   load	   in	  the	   lungs	  [24],	  
with	  values	  approximately	  20–200	  fold	  higher	  than	  those	  observed	  in	  lung	  following	  PMED	  immunization.	  
This	   effect	   was	   noted	   for	   both	   gag	   and	   gag-­‐env	   immunized	   animals.	   It	   may	   be	   that	   the	   quality	   and/or	  
magnitude	  of	  the	  immune	  response	  induced	  mucosally	  to	  gag	  or	  gag-­‐env	  caused	  enhanced	  virus	  replication	  
in	  the	  lung	  compared	  to	  immune	  responses	  induced	  systemically.	  
	  
In	   the	  present	   study,	   the	   relationship	  between	  p25	  staining	  and	  provirus	   load	  was	  discrepant	   in	   that	   the	  
frequency	   of	   positive	   p25	   sections	  was	   significantly	   lower	   than	   controls	   in	   gag-­‐env	   +	   gag-­‐env-­‐ifn	   groups	  
combined	   while	   the	   values	   obtained	   for	   provirus	   load	   in	   gag	   +	   gag-­‐ifn	   and	   env	   +	   env-­‐ifn	   were	   not	  
significantly	   different	   from	   controls.	  However,	   the	   frequency	  of	   provirus	   positive	   samples	   in	   the	   gag-­‐env	  
and	   gag-­‐env-­‐ifn	   groups	   also	   tended	   to	   be	   lower	   than	   controls	   using	   the	   right	   caudal	   lung	   lobe,	   and	   it	   is	  
possible	  that	  the	  discrepancy	  is	  simply	  due	  to	  efficiency	  differences	  between	  immunostaining	  and	  real-­‐time	  
PCR	  methods	  or	  the	  use	  of	  only	  one	  lung	  section	  for	  immunostaining.	  
	  
Evidence	  for	  virus	  replication	  was	  also	  sought	  previously	  following	  mucosal	   immunization	  [24]	  by	  staining	  
sections	  from	  the	  right	  caudal	  lung	  lobe	  for	  the	  p25	  core	  protein.	  No	  significant	  differences	  in	  the	  frequency	  
of	  p25	  positive	  staining	  were	  found	  for	  gag	  or	  env	  immunization	  after	  respiratory	  immunization	  compared	  
to	  controls	  [24].	  However,	  the	  frequency	  of	  p25	  observed	  in	  animals	  immunized	  with	  gag-­‐env	  was	  zero	  in	  
the	   present	   study	   and	   low	   (6.7%;	   p	   =	   0.081)	   in	   the	  mucosal	   study	   [24].	   Since	   the	   provirus	   loads	   in	   lung	  
tissue	   were	   similar	   to	   controls	   following	   PMED	   immunization	   and	   very	   high	   following	   mucosal	  
immunization,	   it	   follows	  that	   there	   is	  a	  disconnection	  between	  provirus	   load	   levels	  and	  p25	  staining.	   It	   is	  
conceivable	   that	   two	   types	   of	   immune	   response	   are	   operating	   concomitantly:	   one	   that	   stimulates	   virus	  
replication,	  and	  one	   that	   recognises	  and	  eliminates	  productively	   infected	  cells.	  VMV-­‐specific	  CD4+	  T	  cells	  
have	  been	  shown	  to	  enhance	  virus	  replication	  in	  target	  cells	  [10]	  and	  such	  cells	  could	  have	  played	  a	  role	  in	  
enhancing	   provirus	   loads	   in	   the	   PMED	   and	   mucosal	   [24]	   studies.	   As	   noted	   above,	   CTL	   precursors	   were	  
observed	   in	   blood	   the	   present	   study,	   and	   it	   is	   possible	   that	   they	   could	   have	   reduced	   the	   levels	   of	  
productively	   infected	   cells	   in	   the	   lung.	  However,	   the	  CTL	   response	  was	  weak	   and	   therefore	   this	   effector	  
mechanism	  appears	  to	  have	  a	  limited	  role	  in	  controlling	  virus	  levels.	  
	  
To	  determine	  whether	   IFN-­‐γ	  would	  enhance	   immune	  responses	  to	  VMV	  immunogens,	  the	   ifn-­‐γ	  gene	  was	  
included	  in	  the	  immunizing	  mixture.	  However,	  the	  presence	  of	  ifn	  in	  the	  immunizing	  mixture	  did	  not	  alter	  
the	  provirus	  DNA	  load	  but	  it	  did	  result	  in	  decreased	  p25	  expression	  in	  the	  lungs.	  Previously,	  we	  also	  could	  
not	  find	  a	  significant	  effect	  of	  ifn	  when	  immunizing	  sheep	  mucosally	  against	  VMV	  [24].	  So,	  the	  lowering	  of	  
the	  blood	  provirus	  load	  observed	  here	  is	  likely	  to	  be	  due	  mainly	  to	  gag	  immunization	  with	  little	  contribution	  
from	  the	  ifn	  gene.	  However,	  the	  tendency	  towards	  reduced	  p25	  staining	  found	  in	  animals	  that	  received	  the	  
ifn	  gene	  suggests	  an	  anti-­‐viral	  effect	  that	  operates	  in	  the	  later	  stages	  of	  virus	  replication.	  
	  To	   assess	  whether	   IFN-­‐γ	   production	   following	   immunization	  might	   play	   a	   role	   in	   control	   virus	   levels,	  we	  
measured	   the	   levels	   of	   IFN-­‐γ	   transcript	   in	   PBMCs.	   The	   results	   showed	   that	   IFN-­‐γ	   expression	   was	   not	  
elevated	   in	   animals	   immunized	   with	   the	   gag	   gene.	   Elevated	   IFN-­‐γ	   expression	   was	   observed	   in	   animals	  
receiving	   env	   immunogens	   in	   response	   to	   p25,	   and	   this	   potentially	   could	   have	   had	   an	   anti-­‐viral	   effect.	  
However,	  the	  provirus	  load	  in	  blood	  was	  not	  different	  from	  controls	  in	  env	  immunized	  animals,	  suggesting	  
that	  IFN-­‐γ	  expression	  in	  blood	  is	  poorly	  associated	  with	  viral	  load	  in	  the	  studied	  tissues.	  The	  results	  suggest	  
that	   IFN-­‐γ	   induced	  by	   immunization	  may	  not	  have	  contributed	  to	  the	  anti-­‐viral	  effect	  observed,	  though	  a	  
direct	  monitoring	  of	  IFN-­‐γ	  mRNA	  expression	  in	  the	  lung	  tissue	  may	  clarify	  this	  point.	  
	  
PMED	  immunization	  with	  VMV	  gag	  or	  env	  genes	  did	  not	  prevent	  lesions	  developing	  in	  the	  lung	  and	  draining	  
lymph	   node.	   This	   is	   in	   contrast	   to	   the	   results	   obtained	   following	  mucosal	   immunization	   [24]	   where	   gag	  
immunization	   induced	   a	   significant	   reduction	   in	   lesion	   scores.	   The	   results	   suggest	   again	   that	   the	   quality	  
and/or	  quantity	  of	  the	  immune	  response	  in	  terms	  of	  controlling	  virus	  replication	  and	  expression	  may	  differ	  
significantly	  following	  PMED	  and	  mucosal	  immunization.	  
Indeed,	  in	  the	  present	  study	  env	  immunization	  with	  ifn	  resulted	  in	  increased	  frequency	  and	  severity	  of	  the	  
lesions.	  When	  the	  env	  gene	  was	  combined	  with	  the	  gag	  gene	  for	  immunization,	  the	  lesion-­‐enhancing	  effect	  
of	  env	  was	  abrogated.	  It	  is	  well	  recognized	  that	  anti-­‐ENV	  antibody	  levels	  correlate	  with	  the	  development	  of	  
arthritis	  in	  goats	  infected	  with	  CAEV	  [39].	  Since	  the	  target	  organs	  affected	  by	  SRLV	  develop	  similar	  lesions	  
consisting	  of	   the	  presence	  of	   inflammatory	  cells,	   inflammation,	  and	  thickening	  of	   tissue,	   the	  mechanisms	  
operating	  may	  be	  similar.	  Thus,	  the	  lesions	  in	  the	  lungs	  could	  have	  been	  due	  to	  immune	  complex	  formation	  
or	  to	  binding	  of	  these	  antibodies	  to	  virus-­‐infected	  cells	  and	  activation	  of	  antibody-­‐dependent	  cell-­‐mediated	  
cytotoxicity.	   Another	   possibility	   is	   that	   anti-­‐ENV	   T	   cell	   responses	   were	   responsible	   for	   the	   lesion	  
enhancement	  [10].	  
However,	   recent	   vaccination	   studies	   in	   goats	   and	   sheep	   have	   shown	   that	   env	   immunization	   can	   induce	  
lower	  virus	   loads	  or	  disease	   [12]	  and	   [19].	   Significant	  differences	  between	   these	   studies	  and	   the	  present	  
work	  exist.	  In	  the	  study	  by	  Gonzalez	  et	  al.	  [19],	  PMED	  immunization	  was	  carried	  out	  via	  vulva	  rather	  than	  
epidermis.	  More	  efficient	  transfection	  of	  dendritic	  cells	  with	  the	  env	  gene	  by	  particle	  bombardment	  due	  to	  
the	  absence	  of	  a	  keratin	  layer	  in	  mucosal	  tissue	  may	  have	  enhanced	  the	  env	  expression	  and	  induced	  local	  
anti-­‐ENV	  antibody	  responses,	  resulting	  in	  decreased	  virus	  load	  in	  blood.	  
In	  conclusion,	  PMED	  immunization	  with	  VMV	  gag	  or	  gag-­‐env	  genes	  provides	  a	  degree	  of	  protection	  against	  
provirus	  DNA	  load,	  whereas	  immunization	  with	  the	  env	  gene	  results	  in	  enhanced	  lesion	  development.	  The	  
findings	   that	   systemic	   immunization	  with	   the	  gag	  gene	   results	   in	  a	   reduced	  blood	  provirus	   load	  and	   that	  
mucosal	  immunization	  with	  gag	  results	  in	  reduced	  lesion	  formation	  [24]	  are	  consistent	  with	  observations	  in	  
HIV	   vaccination	   whereby	   gag-­‐specific	   responses	   are	   protective	   [40].	   The	   PMED	   immunization	   strategy	  
applied	  using	  the	  single	  gag	  gene	  as	  immunogen	  may	  limit	  spread	  of	  infection	  via	  the	  blood	  to	  other	  tissues	  
and	  warrants	  further	  study	  for	  the	  development	  of	  SRLV	  vaccines.	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